The media has gone to town on the issue of insider trading by powerful Congressmen.

Noble Biomaterials, the Pennsylvania-based bacterial management solutions provider, raised $8 million from Northwater Capital’s Intellectual Property Fund and investors including TL Ventures and Dupont Capital Management.

At NYSE Euronext, the question is: What now?

It invested so much--some might say it bet the farm--on inking a deal with Deutsche Bourse, that it must now fight the perception that it is merely listing. To be sure, the top executives always knew the fight would be difficult, but deep down they were pretty confident they could make it work. They couldn’t. And CEO Duncan Niederauer now has plenty to prove. Most think he will pursue some sort of deal, albeit on a less grand scale.

Banks had already reserved against losses stemming from the mortgage settlement that was hammered out with state and federal regulators. We suggested that those reserves were probably adequate. JPMorgan Chase has said that the bank will not likely have to add to reserves to cover the settlement. The bank will incur some costs to implements the remediation requirements, but the total costs are not likely to be material. Article